Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pollogen, the developer of the TriPollar brand, is a leading medical aesthetics company specializing in innovative energy-based technologies for professional and home-use markets. The company's core technology, TriPollar, is a third-generation radiofrequency (RF) system designed to deliver focused energy to the skin and subcutaneous layers to stimulate collagen production and reduce fat cell volume. Pollogen's portfolio includes the Geneo facial treatment system and the TriPollar STOP and POSE home devices, which are marketed globally for skin tightening, wrinkle reduction, and body contouring. Founded in 2006 and headquartered in Israel, Pollogen was acquired by Lumenis in 2015, integrating its advanced RF solutions into one of the world's largest energy-based medical device companies. The company's products are characterized by their non-invasive nature and clinical efficacy, targeting both the dermis and hypodermis to achieve long-lasting aesthetic results.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TriPollar.